Monday, May 20, 2024
HomePosts Tagged "Data Monitoring Committee"

Late last year Novartis announced termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment; 8,609 patients from 36 countries were involved. There was an increased incidence after 18-24 months of non-fatal stroke, kidney complications, hyperkalemia (high potassium levels) and hypotension

Read More